Fennec Pharmaceuticals Hits Day Low of CAD 10.95 Amid Price Pressure

Fennec Pharmaceuticals, Inc. experienced a significant decline today, with its stock price dropping by 7.12%. The stock reached an intraday low of CAD 10.95, reflecting ongoing challenges within the company. Over the past week, Fennec has seen a total decline of 10.1%, contrasting sharply with the S&P/TSX 60, which gained 2.02% during the same period. In terms of longer-term performance, Fennec's one-year return stands at 11.62%, significantly lagging behind the S&P/TSX 60's impressive 27.5% return. The company's market capitalization is currently CAD 398 million, categorizing it as a small-cap entity within the pharmaceuticals and biotechnology sector. Fennec's financial metrics indicate a weak long-term fundamental strength, highlighted by a negative book value and a concerning EBIT to interest ratio of -11.26. Recent financial results show a notable decline in net sales and net profit, with net sales for the half-year at CAD 25.91 million, down 41.32%, and a net profit loss of CAD 6.03 million, reflecting a staggering growth decline of 161.99%. These figures underscore the challenges facing Fennec Pharmaceuticals as it navigates a competitive market landscape.